This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Delving into the recent results of the phase 2b APIPPRA clinical trial of Orencia (Abatacept) in patients with a high risk of developing rheumatoid arthritis
Ticker(s): BMYWho's the expert?
Institution: The Arthritis Group
- Practicing Rheumatologist at The Arthritis Group who is board certified in Rheumatology and Geriatrics.
- Manages 75-85 patients with Rheumatoid Arthritis per month.
- Previously an Assistant Professor of Geriatrics at Temple University and currently a member of the American College of Rheumatology and the Philadelphia Medical Society.
Interview Goalto discuss the current standard of care and the use of Orencia (Abatacept) to prevent the progression of rheumatoid arthritis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
